Company intelligence / Profile preview
Rezolute, Inc.
Redwood City, California, United Statesrezolutebio.com ↗
- Ownership
- Public · RZLT
- Employees
- ~59
- Development stage
- Phase 3
01
Overview
Rezolute is conducting a Phase 3 clinical trial for ersodetug (RZ358), a human monoclonal antibody for the treatment of congenital hyperinsulinism. They also have RZ402, an oral plasma kallikrein inhibitor in Phase 2 clinical trial for diabetic macular edema. Recent publications indicate positive outcomes from an expanded access program for compassionate use of ersodetug for hypoglycemia due to tumor hyperinsulinism[4][5].
- Therapeutic areas
- OphthalmologyEndocrinology
- Modalities
- Monoclonal antibodiesOral plasma kallikrein inhibitor
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $352.1M
- Total revenue
- $0
- Enterprise value
- $262.8M
Beyond the preview
Go deeper on Rezolute, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rezolute, Inc..